Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3531804 | 0.85 | TSHR (0.40) | ALDH1A1KDM4EMAPTTDP1HSD17B10 | |
| SCHEMBL3535699 | 0.80 | GPR3 (0.39) | KDM4ENPC1RAB9AHSD17B10SMN1; SMN2 | |
| SCHEMBL5782305 | 0.77 | BACE1 (0.40) | ALDH1A1KDM4EMAPTL3MBTL1TDP1 | |
| SCHEMBL142461 | 0.73 | CYP2A6 (0.48) | KDM4EL3MBTL1HPGD | |
| SCHEMBL13502296 | 0.71 | KDM4E (0.65) | ALDH1A1KDM4EMAPTL3MBTL1TDP1 | |
| SCHEMBL5544963 | 0.70 | ALDH1A1 (0.41) | ALDH1A1KDM4EMAPTL3MBTL1TDP1 | |
| SCHEMBL21798536 | 0.69 | TSHR (0.45) | ALDH1A1KDM4EMAPTHSD17B10MEN1 | |
| SCHEMBL14409805 | 0.68 | KDM4E (0.51) | ALDH1A1KDM4EMAPTL3MBTL1TDP1 | |
| SCHEMBL788146 | 0.68 | CYP2A6 (0.56) | ALDH1A1KDM4EMAPTL3MBTL1TDP1 | |
| Hydrochloric Acid SCHEMBL15910545 | 0.68 | BACE1 (0.49) | ALDH1A1KDM4EMAPTL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373233-B1 | DERIVATIVES OF N-(ARYLSULFONYL)BETA-AMINOACIDS COMPRISING A SUBSTITUTED AMINOMETHYL GROUP, THE PREPARATION METHOD THEREOF AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2007-09-05 | — | — | EP | claimed |
| US-7157454-B2 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2007-01-02 | — | — | US | claimed |
| US-20040116353-A1 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI (FR) | 2004-06-17 | — | — | US | claimed |
| CN-115716849-A | Synthetic method of aryl phosphorus compound | 海南大学 | 2023-02-28 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | disclosed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7425631-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-09-16 | — | — | US | disclosed |
| WO-2006044355-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| EP-1633743-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | Amgen, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | disclosed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004092164-A1 | CYCLIC AMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF INFLAMMATION-RELATED DISORDERS MEDIATED BY BRADYKININ | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040116353-A1 | Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same | SANOFI (FR) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | ALDH1A1 353/4885KDM4E 2759/4885MAPT 2176/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | ALDH1A1 353/4885KDM4E 2759/4885MAPT 2176/4885 |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | ALDH1A1 158/4885KDM4E 1662/4885MAPT 3668/4885 |
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | ALDH1A1 184/4885KDM4E 2594/4885MAPT 3351/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | ALDH1A1 616/4885KDM4E 1806/4885MAPT 2664/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | ALDH1A1 81/4885KDM4E 3048/4885MAPT 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.